SCHEMBL24256903

SCHEMBL24256903

CCCc1nc2oc(C(=O)O)c(N)c2c2c1CCC2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.56
ALDH1A1 P00352 9/20 0.56
HPGD P15428 6/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C19 P33261 1/20 0.56
MAPK1 P28482 3/20 0.54
MAPT P10636 2/20 0.54
HTT P42858 1/20 0.54
TSHR P16473 4/20 0.50
GAA P10253 4/20 0.50
POLB P06746 3/20 0.50
HSD17B10 Q99714 3/20 0.50
KMT2A Q03164 2/20 0.50
RECQL P46063 1/20 0.50
XBP1 P17861 1/20 0.50
OPRK1 P41145 1/20 0.47
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256901 0.86 KDM4E (0.77) KDM4EALDH1A1HPGDCYP1A2CYP3A4
SCHEMBL24256672 0.73 KMT2A (0.51) KDM4EALDH1A1HPGDCYP1A2CYP3A4
SCHEMBL24256648 0.72 KDM4E (0.62) KDM4EALDH1A1HPGDMAPK1MAPT
SCHEMBL24256646 0.64 KDM4E (0.77) KDM4EALDH1A1HPGDCYP1A2CYP3A4
SCHEMBL29229877 0.64 KDM4E (0.72) KDM4EALDH1A1HPGDCYP1A2CYP3A4
SCHEMBL24256905 0.63 KDM4E (0.48) KDM4EALDH1A1HPGDCYP1A2CYP3A4
SCHEMBL2792954 0.59 PPARG (0.38) ALDH1A1HPGDCYP2C19MAPTTSHR
SCHEMBL849074 0.58 CYP1A2 (0.48) KDM4EALDH1A1CYP1A2MAPTTSHR
SCHEMBL17009098 0.57 ALDH1A1 (0.34) KDM4EALDH1A1HPGDCYP1A2CYP3A4
SCHEMBL28913746 0.57 L3MBTL1 (0.36) KDM4EALDH1A1CYP1A2CYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 KDM4E 1927/4885ALDH1A1 1934/4885HPGD 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.